UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1206-10
Program Prior Authorization/Notification
Medication Continuous glucose monitors, sensors and transmitters (all brands)
P&T Approval Date 12/2016, 11/2017, 11/2018, 11/2019, 3/2020, 6/2021, 6/2022, 8/2023,
11/2024
Effective Date 2/1/2025
1. Background:
Continuous glucose monitors may be used by patients with diabetes who require glucose
monitoring beyond what can be achieved with a standard blood glucose monitor.
2. Coverage Criteria:
A. Initial Authorization
1. Continuous glucose monitors, sensors, and transmitters will be approved for initial
therapy based on both of the following criteria:
a. Diagnosis of diabetes
-AND-
b. All of the following:
(1) Patient is motivated and knowledgeable about use of continuous glucose
monitoring
(2) Patient is adherent to diabetic treatment plan
(3) Patient participates in ongoing education and support
Authorization will be issued for 12 months.
B. Reauthorization
1. Continuous glucose monitors, sensors, and transmitters will be approved for
continuation of therapy based on the following criterion:
a. Documentation of positive clinical response
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Medical Necessity may be in place.
4. References:
1. American Diabetes Association. Diabetes Technology: Standards of Care in Diabetes - 2023.
Diabetes Care December 2022, Vol.46, S111-S1272. Lane AS, Mlynarczyk MA, de Veciana M,
et al. Real-time continuous glucose monitoring in gestational diabetes: a randomized controlled
trial. Am J Perinatol. 2019 Jul;36(9):891-897.
3. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine
Society clinical practice guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574.
Program Prior Authorization/Notification – Continuous Glucose Monitors
Change Control
12/2016 New program.
11/2017 Annual review. Revised reauthorization criteria.
11/2018 Annual review. Revised authorization timeline, added criteria for
insulin use.
5/2/2019 Administrative change. Change Oxford effective date to 6/1/2019.
11/2019 Modified criteria to allow coverage for any type of diabetes.
3/2020 Added requirement that patient is knowledgeable about continuous
glucose monitors, participates in education and support, and monitors
blood glucose 3 or more times per day.
6/2021 Modified criteria to monitor blood glucose 4 or more times per day and
added criteria that patient has inadequate glycemic control despite an
intensive diabetes management.
6/2022 Removed requirements that patient is on an intensive insulin regimen,
has inadequate glucose control, and regularly monitors blood glucose at
least 4 times per day.
8/2023 Annual review. Updated references.
11/2024 Annual review. Updated references.
© 2024 UnitedHealthcare Services, Inc.
2